Published in Medical Verdicts and Law Weekly, November 25th, 2004
"These funds will be applied to requirements associated with the launch of our diabetes drug, Sucanon, in Mexico including purchase of television and radio time, in-store support for Sucanon and medical presentations," Rieveley said.
"We have to date received $111,000 of the above private placement funding. Shares pursuant to this funding will be issued at $.50 Cdn, with each share having a 2-year warrant exercisable at CDN $0.55. The U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly